News Center

‌1. IFCC Accreditation & Lifotronic's Excellence

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), established in 1952, is the global authority in clinical chemistry and laboratory medicine. Its Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) is a leading institution for cardiac biomarker standardization. Lifotronic's hs-cTnI STAT, hs-cTnT STAT, NT-proBNP, and NT-proBNP STAT assays have passed IFCC's rigorous evaluation and been included in its updated High Sensitivity Cardiac Troponin I and T Assay Analytical Characteristics reference table, IFCC Cardiac Troponin Interference Table, BNP NT-proBNP and MR-proANP Assays Analytical Characteristics reference table and IFCC Natriuretic Peptide Interference Table (v082025). This accreditation confirms that Lifotronic's technologies achieve internationally leading sensitivity and accuracy, providing reliable foundations for clinical diagnostics.

Cardiac troponin I/T (cTnI, cTnT) and natriuretic peptides (including BNP/NT-proBNP) are core biomarkers for myocardial infarction (MI) and heart failure (HF) diagnosis ^[1,2,3]. Lifotronic's listed assays demonstrate exceptional performance in the reference tables, with hs-cTnI STAT covering 1.5–50,000 ng/L and NT-proBNP STAT 5–35,000 ng/L — both meeting global benchmarks. The electrochemiluminescence (ECL) technology enables ultra-rapid 9-minute testing and superior anti-interference capacity, making them critical tools for emergency settings.

2. Racing Against Time: 9-Minute Cardiac Testing

Lifotronic's ECL platform utilizes ruthenium-labeled monoclonal antibodies for precise antigen-antibody binding, combined with magnetic bead immobilization and electrically stimulated luminescence. As the state-of-the-art chemiluminescence method, it offers:

-Ultra-short reaction time

-High signal intensity & stability

-Minimal environmental interference

Outperforming direct/enzyme-linked chemiluminescence.

Clinically, high-sensitivity troponin (hs-cTn) is the gold standard for myocardial injury ^[2,4], while natriuretic peptides are sensitive indicators of cardiac function ^[3,5]. Lifotronic's STAT series products (hs-cTnI STAT, hs-cTnT STAT, NT-proBNP STAT) achieve 9-minute emergency testing, drastically reducing turnaround time (TAT) to secure golden treatment windows for MI/HF patients.

3. Comprehensive Support for Cardiovascular Disease Diagnosis

Lifotronic’s emergency rapid-testing portfolio now covers a full spectrum of cardiac biomarkers, including:

‌High-sensitivity troponin I/T (hs-cTnI, hs-cTnT)‌

‌Myoglobin (MYO)‌

‌Creatine kinase-MB (CK-MB)‌

‌B-type natriuretic peptide (BNP)‌

‌N-terminal pro-BNP (NT-proBNP)‌

‌Heart-type fatty acid-binding protein (H-FABP)‌

‌

Powered by its ‌dual advantages of speed (9-minute testing) and accuracy (IFCC-certified)‌, Lifotronic’s technology matrix has been adopted by leading medical institutions worldwide, delivering ‌end-to-end solutions‌ for cardiovascular disease diagnosis and management.

Reference：

[1] Saenger AK, Jaffe AS, Body R, Collinson PO, Kavsak PA, Lam CSP, Lefèvre G, Omland T, Ordóñez-Llanos J, Pulkki K, Apple FS. Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). Clin Chem Lab Med. 2019 Apr 24;57(5):633-640.

[2] Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191. Erratum in: Eur Heart J. 2024 Apr 1;45(13):1145.

[3] Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, Chioncel O, Defilippi CR, Drazner MH, Felker GM, Filippatos G, Fiuzat M, Ide T, Januzzi JL Jr, Kinugawa K, Kuwahara K, Matsue Y, Mentz RJ, Metra M, Pandey A, Rosano G, Saito Y, Sakata Y, Sato N, Seferovic PM, Teerlink J, Yamamoto K, Yoshimura M. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. J Card Fail. 2023 May;29(5):787-804.

[4] ‌Chinese Society of Cardiology, Chinese Journal of Cardiology Editorial Board. Expert Consensus on the Diagnosis and Treatment of Acute Myocardial Infarction in Young Adults [J]. Chinese Journal of Cardiology Editorial Board,2025,53(02):110-120.

[5] Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. Chinese Society of Cardiology, Chinese College of Cardiovascular Physicians, Heart Failure Committee of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese Journal of Cardiology,2024(03).